Segura C, Foz A, Fuster C, Tirado M, Roy C
Med Clin (Barc). 1981 Jun 25;77(2):50-5.
Cefsulodin is a new second generation cephalosporin with a narrow antibacterial spectrum. Its main use is in the treatment of Pseudomonas aeruginosa infections. It is resistant to the action of the beta-lactamases of gram negative bacilli, especially to that of the cephalosporinases. We have studied 170 strains of P. aeruginosa and 10 of other species of Pseudomonas, determining the MIC by the serial dilution test in solid medium and the sensitivity by the agar diffusion test. With 8 microgram/ml, a concentration which is accepted as a limit of sensitivity from the therapeutic point of view, 90% of the P. aeruginosa strains studied are inhibited; the MIC50 is obtained with 2 microgram/ml. Within the strains considered sensitive (MIC less than 8 microgram/ml) there is a marked dispersion of the zone diameters corresponding to each of the values of MIC. This behavior limits the value of the regression line. We have also studied the MIC of carbenicillin for nearly all the strains and we have also studied the MIC of carbenicillin for nearly all the strains and we have found that 86.58% are sensitive to both preparations, 4.96% are sensitive to cefsulodin and resistant to carbenicillin, 4.02% resistant to cefsulodin and sensitive to carbenicillin and 4.69% are resistant to both preparations. From the clinical point of view the number of strains sensitive (or resistant) is similar with both substances but cefsulodin is in absolute values from 8 to 128 times more day active than carbenicillin. Cefsulodin is administered by a parenteral route and is eliminated by the urine in active form. The recommended therapeutic dose for the treatment of systemic infections is 2 g daily IV. This dose may be increased if it is considered advisable. There is good local tolerance (IM and IV), it is only slightly toxic, hardly alters the intestinal flora and may be used at all ages, in patients with immunological alterations and in patients with an altered renal function.
头孢磺啶是一种新型第二代头孢菌素，抗菌谱窄。其主要用途是治疗铜绿假单胞菌感染。它对革兰氏阴性杆菌的β-内酰胺酶作用具有抗性，尤其对头孢菌素酶有抗性。我们研究了170株铜绿假单胞菌和10株其他假单胞菌属菌种，通过固体培养基中的连续稀释试验测定MIC，并通过琼脂扩散试验测定敏感性。从治疗角度来看，8微克/毫升的浓度被视为敏感性极限，所研究的90%的铜绿假单胞菌菌株受到抑制；MIC50为2微克/毫升。在被认为敏感的菌株（MIC小于8微克/毫升）中，对应于每个MIC值的抑菌圈直径存在明显差异。这种行为限制了回归线的值。我们还研究了几乎所有菌株对羧苄西林的MIC，发现86.58%的菌株对两种制剂均敏感，4.96%的菌株对头孢磺啶敏感而对羧苄西林耐药，4.02%的菌株对头孢磺啶耐药而对羧苄西林敏感，4.69%的菌株对两种制剂均耐药。从临床角度来看，两种药物敏感（或耐药）的菌株数量相似，但头孢磺啶的日活性绝对值比羧苄西林高8至128倍。头孢磺啶通过胃肠外途径给药，并以活性形式经尿液排出。治疗全身性感染的推荐治疗剂量为每日静脉注射2克。如果认为合适，该剂量可以增加。局部耐受性良好（肌肉注射和静脉注射），毒性很小，几乎不改变肠道菌群，可用于所有年龄段、免疫功能改变的患者以及肾功能改变的患者。
